Recipients of an implantable cardioverter-defibrillator who do not meet guideline-recommended eligibility criteria are at elevated risk for in-hospital complications.
Medical decision making is under increased scrutiny, particularly when it involves the use of costly technology. These investigators studied data from the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator (ICD) Registry to determine the number, characteristics, and outcomes of patients who received ICDs outside current evidence- and guideline-based parameters.
According to current guidelines, ICDs are not recommended for primary prevention of sudden cardiac death within 40 days after an acute myocardial infarction (MI) or in patients with New York Heart Association (NYHA) class IV heart failure symptoms, in those recovering from coronary artery bypass grafting (CABG), or in those with a new heart failure diagnosi…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association